Average residual limb pain
| Group 1 | Group 2* | |||
| Average RLP (SD, N) | Average reduction from BL (SD) | Average RLP (SD, N) | Average reduction from BL (SD) | |
| Baseline | 6.4 (1.0, 7) | n/a | 6.4 (1.3, 11) | n/a |
| Week 4 | 4.2 (2.6, 7) | 2.1 (2.6) | 4.8 (1.7, 11) | 1.7 (1.6) |
| Week 8 (EOT) | 3.9 (1.7,7) | 2.5 (2.2) | 4.8 (2.2, 11) | 1.7 (1.8) |
| Month 3 | 2.4 (1.5, 5) | 4.0 (1.2)† | 4.8 (3.4, 8) | 1.0 (2.9) |
| Month 12 | 2.3 (1.2, 3) | 4.3 (1.5)† | 3.2 (2.5, 4) | 1.0 (2.0) |
*Group 2 crossed over at week 4 to receive 4 weeks of active stimulation.
†P<0.05 compared with group 2 at the end of the placebo period.
BL, baseline; EOT, end of treatment; n/a, not applicable; RLP, residual limb pain.